Lung Cancer

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

First-line treatment with the combination of amivantamab and lazertinib resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

Treatment with the combination of sotorasib carboplatin, and pemetrexed produced responses and demonstrated safety in patients with KRAS G12C–mutated, advanced non–small cell lung cancer, according to data from the phase 1/2 CodeBreaK 101 trial.

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.

Andrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.

The FDA has granted fast track designation to MYTX-011 for use as a potential therapeutic option in patients with non–small cell lung cancer and cMET overexpression.

Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

Jonathan W. Riess, MD, MS, discusses preliminary results from a phase 2 trial of the IO102-IO103 immuno-modulating cancer vaccine plus pembrolizumab in patients with metastatic non–small cell lung cancer adenocarcinoma.

Joachim G. J. V. Aerts, MD, PhD, discusses findings from the phase 3 DENIM trial in patients with mesothelioma, which was presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

The 18th Annual New York Lung Cancers Symposium, scheduled for November 11, 2023, as a live meeting in New York, New York, boasts an agenda that covers a broad range of modern clinical topics.

Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.

The first-line combination of pembrolizumab, lenvatinib, pemetrexed, and platinum-containing chemotherapy did not meet the dual primary end points of overall survival and progression-free survival compared with pembrolizumab plus pemetrexed and platinum-containing chemotherapy in patients with metastatic, nonsquamous non–small cell lung cancer in whom EGFR-, ALK- or ROS1-directed therapies were not indicated.

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy, followed by surgery and adjuvant nivolumab monotherapy, generated a statistically significant and clinically meaningful improvement in event-free survival vs neoadjuvant chemotherapy plus placebo, followed by surgery and adjuvant placebo, in patients with resectable stage IIA to IIIB non–small cell lung cancer.

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.

Melissa L. Johnson, MD, spotlights the early-phase investigation of ifinatamab deruxtecan in advanced solid tumors, discusses the efficacy and safety of the agent in patients with small cell lung cancer, and emphasizes how results from a subgroup analysis support its continued investigation.

Stephen V. Liu, MD, discusses the 5-year overall survival data with atezolizumab and chemotherapy in patients with extensive-stage small cell lung cancer.

Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.